Dosage form for treating dysthymia

• US 5,246,711 A
• Filed: 09/10/1992
• Issued: 09/21/1993
• Est. Priority Date: 02/27/1992
• Status: Expired due to Term

• Current Assignee: Encinal Pharmaceutical Investments, LLC
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Ayer, Atul D., Ridzon, Dana
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): BROUILLETTE, D GABRIELLE
• Application Number:
  US07/943,618
• Time in Patent Office: 376 Days
• Field of Search: 424/473, 424/468
• US Class Current: 424/473
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A dosage form is provided for administering a drug of the formula ##STR1## to a patient to produce an anxiolytic benefit in the patient.

Claims

1. A buccal dosage form for administering tandopsirone to the buccal-mucosal environment of a patient in need of tandospirone therapy, wherein the buccal dosage form comprises:

(a) a wall comprising a member selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, and cellulose triacetate, which wall surrounds;

(b) an internal lumen;

(c) an exit passageway in the wall that connects the buccal-mucosal environment with the internal lumen;

(d) a push composition in the lumen, comprising an osmotically fluid-activated agent, that in the prescence of buccal-mucosal fluid that enters the lumen, increases in volume and thereby occupies space in the lumen, and wherein the buccal dosage form is characterized by;

(e) a buccal-mucosal composition comprising 1 mg to 750 mg of tandospirone, a poly(O--CH₂ CH₂)_n wherein n is 4,000 to 5,500, a different poly(O--CH₂ CH₂)_n wherein n is 6,500 to 7,400, and wherein the buccal-mucosal composition, when administered by the dosage form to the patient, provides tandospirone for treating depression, major depression accompanied by melancholia, dysthymia, cyclothymia and anxiolytic.